Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products

Patent Number: 6960351

One of the main drawbacks of stem cell therapy, or any cell therapy for that matter is that it is important to avoid the issue of immunological rejection. This is why numerous scientists are using autologous stem cells. Unfortunately, there is no such thing as autologous embryonic stem cells. Additionally, the ability to use allogeneic stem cells without rejection would allow for the widespread use of "of the shelf" cell lines. This patent teaches a way to "immunoisolate" cells by placing them in a specialized chamber. The one independent claim of the patent covers the description of this chamber.

View this patent on the USPTO website.